A study on indolent systemic mastocytosis treatments
Part of Cancer, Immune system & allergy clinical trials.
This study is observing adults with indolent systemic mastocytosis (ISM) who are already receiving or planning to start symptom treatments or the drug avapritinib. It aims to learn more about how these treatments work in real life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with indolent systemic mastocytosis (ISM), a milder form of mastocytosis.
- You are currently being treated for ISM symptoms, or you plan to start treatment, including with the drug avapritinib.
- You do not have advanced systemic mastocytosis (a more severe form) or another blood cancer.
- You are not currently taking another KIT inhibitor drug (other than avapritinib).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how avapritinib works in people with indolent systemic mastocytosis whose symptoms are not well controlled by other treatments. You will take the drug as part of your usual care, and researchers will collect information to see how well it helps.
This trial tests BLU-263, a study medicine, against placebo (inactive treatment) to see if it improves symptoms in people with indolent systemic mastocytosis. It also checks safety and how well the dose is tolerated before and during treatment.
This trial tests a new drug called ISM6331 for people with advanced mesothelioma or other solid tumors that have not responded to standard treatments. The drug targets a specific pathway that may help stop tumor growth.
This study looks at people with a slow-growing type of mast cell disease called indolent systemic mastocytosis. The goal is to better understand the condition and how to manage it, using your genetic information to guide future care.
This trial tests a combination of two drugs, avapritinib and decitabine, for people with systemic mastocytosis plus another blood cancer (SM-AHN). The goal is to see if the combination works better than either drug alone.
This study provides access to bezuclastinib, an oral medication, for people with advanced systemic mastocytosis whose current treatment isn't working well enough. The goal is to see if it can help control the disease when other options have not been effective.
Hear when a new Indolent Systemic Mastocytosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.